Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.370
-0.530-2.96%
Volume:4.98M
Turnover:86.67M
Market Cap:46.19B
PE:11.72
High:17.800
Open:17.800
Low:17.180
Close:17.900
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.02
T/O Rate:0.92%
Dividend:0.46
Dividend Rate:2.62%
EPS(LYR):1.482
ROE:7.04%
ROA:1.53%
PB:0.81
PE(LYR):11.72
PS:0.94

Loading ...

Earning Preview: FOSUN PHARMA this quarter’s revenue is expected to increase by 8.56%, and institutional views are broadly bullish

Earnings Agent
·
Aug 18

Fosun Pharma Subsidiary Enters Collaboration Framework and License Agreement

Stock News
·
Aug 17

Shanghai Fosun's Unit in Collaboration with Sandoz AG on 10 Biologic Products

Reuters
·
Aug 17

Shanghai Fosun Pharmaceutical Says to Team up Sandoz on Commercialization, Development, Manufacturing of up to 10 Biologic Products

THOMSON REUTERS
·
Aug 17

Shanghai Fosun Pharmaceutical Says Unit Signs Framework Cooperation Agreement with Sandoz Ag

THOMSON REUTERS
·
Aug 17

FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD

Bulletin Express
·
Aug 13

Fosun Pharma Schedules 25 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 13

Sinopharm Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Aug 11

Fosun Pharma Secures China Approval for Two Drugs

MT Newswires Live
·
Aug 10

Fosun Pharma Subsidiary Secures NMPA Approval for Dobutamine Hydrochloride Injection

Bulletin Express
·
Aug 07

Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express
·
Aug 07

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval

Stock News
·
Aug 07

Shanghai Fosun Pharma - Drug Registration Application for Dobutamine Hydrochloride Injection Approved by Nmpa

THOMSON REUTERS
·
Aug 07

Sinopharm Group Stock Sheds 0.8% in Hong Kong

Dow Jones
·
Aug 07

FOSUN PHARMA Keeps Share Capital Unchanged in July 2026 Monthly Return

Bulletin Express
·
Aug 06

Fosun Pharma Units Get Registration Nod for Two Drugs in China

MT Newswires Live
·
Aug 03

Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market

Bulletin Express
·
Aug 03

Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment

Bulletin Express
·
Aug 03

Shanghai Fosun Pharma - Drug Registration Application for Empagliflozin & Metformin Hydrochloride Sustained-Release Tablets(Iii)Approved by Nmpa

THOMSON REUTERS
·
Aug 03